Novavax Inc. ($NVAX) Stock Forecast: Up 6.1% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company focused on developing innovative vaccines to address infectious diseases. Today, the stock had a strong bullish movement in the market.

Why is Novavax Inc. going up?

NVAX stock is up 6.1% on Apr 30, 2026 14:15

• The upcoming release of Novavax's first-quarter 2026 financial results created excitement among investors.
• A director of the company showed confidence in Novavax's future by exercising Restricted Stock Units (RSUs), which positively influenced investor sentiment.
• Despite recent underperformance, Novavax's stock experienced a notable upturn today, potentially linked to growing optimism about the company's financial prospects and operational achievements.
• The stock's bullish movement may have been influenced by broader market dynamics or sector-specific developments benefitting biotech firms like Novavax.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax investors get first-quarter 2026 results at 8:30 a.m. May 6

Novavax (Nasdaq: NVAX) will report its first-quarter 2026 financial results and operational highlights on May 6, 2026, at 8:30 a.m. ET. A live webcast and conference call will be available, with replay access provided for both phone and webcast. The announcement includes detailed instructions for registration, dial-in numbers, and replay access for investors.

https://www.stocktitan.net/news/NVAX/novavax-to-report-first-quarter-2026-financial-results-on-may-6-l8l0f49mlabs.html

Novavax to Report First Quarter 2026 Financial Results on May 6, 2026

Novavax, Inc. (Nasdaq: NVAX) has announced that it will report its first-quarter 2026 financial results and operational highlights on Wednesday, May 6, 2026, at 8:30 a.m. ET. The company will host a conference call for investors and media to discuss these results, with replay options available for a limited time afterward. Details for registering for the call and accessing the webcast have been provided.

https://finance.yahoo.com/sectors/healthcare/articles/novavax-report-first-quarter-2026-200000793.html

Novavax (NVAX) director exercises RSUs for 9,520 common shares

Novavax Inc. director Charles W. Newton acquired 9,520 common shares through the exercise of Restricted Stock Units (RSUs) on April 25, 2026. These RSUs vest in three equal annual installments beginning April 25, 2025, contingent on his continued service on the Board of Directors. Following this transaction, Newton directly holds 9,520 common shares.

https://www.stocktitan.net/sec-filings/NVAX/form-4-novavax-inc-insider-trading-activity-96543bf3a091.html

Novavax Inc. stock underperforms Tuesday when compared to competitors

Novavax Inc. (NVAX) shares dropped 1.86% to $7.92 on Tuesday, experiencing its second consecutive day of losses. This underperformance occurred during a generally poor trading session, with the NASDAQ Composite Index falling 0.90% and the Dow Jones Industrial Average dipping 0.05%. The company's stock declined relative to its competitors and broader market indices.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-tuesday-when-compared-to-competitors-2a2a7cd8-fa8c129d3fc5?mod=mw_quote_news

Novavax Inc. stock underperforms Monday when compared to competitors

Novavax Inc. (NVAX) shares dropped 1.82% to $8.07 on Monday, underperforming a mixed trading session for the broader market. Despite the NASDAQ Composite Index rising, Novavax closed significantly below its 52-week high.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-monday-when-compared-to-competitors-ba956149-886db6e9977a

Trending Today

Novavax Inc. Price History

02.03.2026 - NVAX Stock was down 5.0%

• An investment firm, Shah Capital Management, significantly increased its stake in Novavax during Q4, showing confidence in the company's future despite the recent stock decline. This move could indicate a long-term positive outlook on NVAX.
• The appointment of Dr. Robert Walker as the new Executive Vice President and Head of Research & Development brings in a seasoned professional with extensive experience in drug and vaccine development. This change in leadership might signal a strategic shift or renewed focus on research and development efforts.
• The underperformance of Novavax's stock compared to its competitors, despite positive quarterly earnings and revenue growth, suggests that market sentiment or external factors may be influencing investor behavior. This disparity could be a result of broader industry trends or specific company challenges that need addressing.
• The departure of the previous R&D chief after a short tenure and the subsequent internal promotion highlight potential internal restructuring within Novavax. This organizational change could be impacting investor confidence and contributing to the stock's bearish movement.

01.03.2026 - NVAX Stock was up 5.0%

• An increase in stake from Shah Capital Management and Novavax's strong quarterly earnings surpassing analyst predictions likely influenced the stock's upward movement.
• The appointment of Dr. Robert Walker as the new Executive Vice President and Head of Research & Development may have boosted investor confidence in the company's future innovation efforts.
• Despite trailing behind its competitors recently, positive updates on leadership changes and financial results appear to have overshadowed these concerns and propelled the stock price higher.

19.02.2026 - NVAX Stock was down 7.8%

• Novavax Inc.'s (NVAX) stock closed 5.92% lower at $10.01 today, showing a strong bearish movement.
• The underperformance of NVAX compared to its competitors and the broader market can be attributed to several factors:
• The company is projected to incur losses for the current quarter and fiscal year despite recent positive earnings surprises, impacting investor sentiment.
• Continuous days of losses, including today, may have led investors to take profits after benefiting from the stock's momentum previously.
• The increase in stake by institutional investors like Farallon Capital Management LLC in NVAX could indicate confidence in the company's long-term potential. However, the mixed analyst outlook and the stock closing below its 52-week high reflect ongoing market uncertainty.
• The bearish movement of NVAX today is a result of profit-taking, investor cautiousness due to projected losses, and the influence of broader market trends on the stock's performance.

20.02.2026 - NVAX Stock was up 5.5%

• Novavax (NVAX) stock saw a significant 5.56% surge to $10.64 today.
• This growth is linked to the company's recent earnings report surpassing expectations, with earnings of $0.11 EPS beating predictions of -$0.66 and a substantial 66.6% year-over-year revenue increase to $136.4 million.
• Although there have been days where the stock didn't perform as well as competitors and the overall market, positive investor sentiment regarding Novavax's earnings surprises and company interest contributed to today's rise.
• Investors are cautiously observing Novavax's high 5.93 debt-to-equity ratio and the average "Hold" rating from brokerages, signaling a wary outlook despite recent positive developments.

30.02.2026 - NVAX Stock was down 5.1%

• Dr. Robert Walker's appointment as the new Executive Vice President and Head of Research & Development at Novavax was received positively, demonstrating the company's commitment to advancing its R&D efforts.
• Despite strong financial results in Q4 2025, the market's bearish reaction may be linked to uncertainties regarding the leadership transition and potential impacts on future vaccine projects.
• Trade ideas and analyses for Novavax on TradingView revealed a mix of bullish and bearish sentiments, highlighting differing investor opinions on the stock's future performance.
• Some traders showed optimism based on technical indicators and fundamental catalysts such as licensing agreements, while others adopted a cautious stance due to stock volatility and the importance of effective risk management strategies.

24.02.2026 - NVAX Stock was down 5.1%

• Novavax's stock showed minimal growth but lagged behind the overall market performance, hinting at negative investor sentiment.
• Regulatory filings by the company disclosed significant occurrences such as payments for milestones, FDA nods, and financial operations, potentially impacting market perception.
• Challenges persist for Novavax, including consecutive days of losses and weaker performance relative to industry peers, raising investor apprehensions.
• With a neutral "Hold" rating from brokerage firms, surpassing earnings, and heightened institutional investor interest, the stock displays a mixed outlook, prompting cautious market behavior.

23.03.2026 - NVAX Stock was down 5.5%

• Novavax's stock has been experiencing volatility, with recent bearish movements following two consecutive days of losses.
• The underperformance of Novavax's stock can be attributed to concerns raised by activist investor Himanshu Shah regarding governance, operational shortcomings, and disappointing sales of its Covid vaccine Nuvaxovid.
• Additionally, the call by PETA for Novavax to investigate experiments using monkeys from a controversial lab may have added negative sentiment to the stock.
• Despite these challenges, Wall Street analyst Mayank Mamtani remains optimistic about Novavax's potential, especially driven by upcoming milestones from its Sanofi partnership.

08.03.2026 - NVAX Stock was up 5.6%

• A major investor in Novavax, Shah Capital, has initiated efforts to revamp the company's board and leadership, citing concerns about previous missteps and lower-than-expected vaccine sales.
• Criticisms from this investor regarding Novavax's direction and management have prompted a shareholder movement, increasing pressure on the company to make changes.
• Shah Capital's decision to vote against board nominees and executive pay has hinted at potential management changes within Novavax, resulting in a rise in the stock's value.
• Investor enthusiasm for Shah Capital's proposals for strategic changes, cost reductions, and a possible company sale has led to a positive market response, indicating optimism for a revitalization in Novavax's performance and shareholder interests.

15.03.2026 - NVAX Stock was up 5.4%

• An increased stake by SHAH CAPITAL MANAGEMENT in Novavax Inc demonstrates confidence in the company's vaccine development potential, despite concerns about overvaluation and poor growth indicators.
• Novavax's pivot towards a diversified pipeline of vaccines, utilizing its protein-based platform and Matrix-M adjuvant technology, is viewed favorably by investors for sustainable growth and reduced reliance on single products.
• The revenue breakdown of the company emphasizes the strong performance of its "Innovative Vaccines" segment, signaling a positive outlook for its vaccine development efforts.
• Despite recent stock price underperformance compared to peers, the long-term value of Novavax and its potential for FDA approvals, successful clinical readouts, and strategic partnerships are driving investor interest and the current bullish movement in the market.

30.03.2026 - NVAX Stock was up 6.1%

• The upcoming release of Novavax's first-quarter 2026 financial results created excitement among investors.
• A director of the company showed confidence in Novavax's future by exercising Restricted Stock Units (RSUs), which positively influenced investor sentiment.
• Despite recent underperformance, Novavax's stock experienced a notable upturn today, potentially linked to growing optimism about the company's financial prospects and operational achievements.
• The stock's bullish movement may have been influenced by broader market dynamics or sector-specific developments benefitting biotech firms like Novavax.

10.03.2026 - NVAX Stock was down 5.2%

• Novavax's stock had a bearish movement despite outperforming competitors and the broader market in the past few days, indicating a shift in investor sentiment.
• The increase in price target to $18 from $16 and maintaining a Buy rating did not seem to positively impact the stock, suggesting other factors are at play.
• Criticisms regarding Novavax's strategy, calls to slash costs, and overhaul the board of directors might have contributed to the bearish movement as investors react to uncertainties surrounding the company's future direction.
• The lackluster Q4 earnings, projected revenue decline, and cash flow concerns highlighted in the analysis post-earnings could have further fueled the negative market sentiment towards Novavax, leading to the bearish movement.

27.02.2026 - NVAX Stock was down 5.5%

• The bearish movement in NVAX stock can be attributed to:
• Overall market underperformance: NVAX's decline occurred during a negative trading session for major indexes like the NASDAQ Composite and Dow Jones Industrial Average.
• Renewed scrutiny and volatility in the biotech sector: Investor attention on Novavax's pipeline updates and financial health amidst post-COVID revenue declines may have added pressure on the stock.
• Technical analysis signals: Algorithmic analysis highlighting a mid-channel oscillation pattern and divergent sentiment across different time horizons might have influenced traders' decisions.
• Despite a brief gain on Monday breaking a losing streak, NVAX continues to struggle to outperform the broader market, indicating ongoing challenges and uncertainties surrounding the company's future prospects.